A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death

BACKGROUND: Clarithromycin, known as a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, may increase the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies. This study aimed to characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesgarpour, Bita, Gouya, Ghazaleh, Herkner, Harald, Reichardt, Berthold, Wolzt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619489/
https://www.ncbi.nlm.nih.gov/pubmed/26497728
http://dx.doi.org/10.1186/s12944-015-0134-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619489/
https://www.ncbi.nlm.nih.gov/pubmed/26497728
http://dx.doi.org/10.1186/s12944-015-0134-y

Ejemplares similares